ATB Therapeutics secures 54 million euros in Series A
Marc Nemitz
| 20.11.2024
ATB Therapeutics secures fresh capital for innovative antibodies. EQT Life Sciences and partners invest in breakthrough antibody therapies for oncology and immunology
Stockholm, November 2024 - EQT Life Sciences, together with MRL Ventures Fund (MRLV), has led a EUR 54 million Series A financing round for Belgian biotech company ATB Ther apeutics. The capital will be used to advance the clinical development of innovative therapeutics for oncology and immunology based on the company's proprietary ATBioFarm platform.
Unique antibody platform as a driver of innovation
The ATBioFarm technology enables the scalable and rapid production of complex biological therapeutics. These antibodies integrate novel cell-killing mechanisms, including enzymatic functions, and offer both improved efficacy and increased safety compared to conventional approaches such as antibody drug conjugates (ADCs).
Our funding demonstrates the confidence of international investors in the ATBioFarm platform. We look forward to expanding our team and developing transformative therapies for patients worldwide.
Bertrand Magy, CEO and co-founder of ATB Therapeutics
With this platform, ATB aims to revolutionize the development of weaponized antibodies - biological therapeutics with highly precise cell-killing properties. In addition to oncology applications, the technology is also aimed at new immunology therapies.
Expansion of infrastructure and management expertise
The funding will be used to expand research and development activities in Ghent and to set up a pilot production facility in Marche-en-Famenne. The facility will serve as a test platform for the next phase of production.
The ability of the ATBioFarm to rapidly generate antibodies with unique cytotoxic and targeting properties is a real gamechanger. This technology opens up new opportunities to address unmet clinical needs
John de Koning, Partner at EQT
In a strategic move, ATB has appointed experienced antibody developer Mark Throsby as Executive Chairman. Throsby, known for his work at Merus, will support ATB in this growth phase. In addition, John de Koning (EQT) and Karin Kleinhans (MRLV) will join the Board of Directors.
International support for biopharma innovation
In addition to EQT and MRL Ventures Fund, V-Bio, VIVES Partners, the Belgian Sovereign Fund SFPIM, Wallonie Entreprendre, Sambrinvest and existing investors also participated in the round. The Région Wallonne is also supporting the company with financial backing.
Newsletter
Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.
LinkedIn ConnectTake care, give care
Did this news inform or entertain you? Then we would be happy if you tell your network about it.
Share on Linkedin Share on Facebook Share on XingFYI: English edition available
Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?
FYI: Deutsche Edition verfügbar
Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?
